Augmentation is a significant problem with dopaminergic therapy for restless legs syndrome (RLS). Evi Holzknecht, MD, Medical University of Innsbruck, Innsbruck, Austria, speaks on future directions to accurately predict dopaminergic augmentation. Currently, known augmentation predictors are the dopaminergic agents, duration of treatment, and dosage of the dopaminergic agent. Studies have also shown that RLS severity before treatment is related to augmentation rates, which means that earlier diagnosis can reduce the risk of augmentation. Dr. Holzknecht believes that identification and monitoring of risk factors such as low iron levels could lead to a shift towards causal first-line therapies and improved patient outcomes. This interview was recorded at the World Sleep Congress 2022 in Rome, Italy.